NASDAQ:BCDA BioCardia (BCDA) Stock Price, News & Analysis $1.01 -0.08 (-7.34%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$1.02 +0.01 (+1.09%) As of 05/15/2026 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About BioCardia Stock (NASDAQ:BCDA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BioCardia alerts:Sign Up Key Stats Today's Range$1.01▼$1.1050-Day Range$1.01▼$1.2952-Week Range$1.00▼$2.49Volume311,625 shsAverage Volume334,365 shsMarket Capitalization$11.05 millionP/E RatioN/ADividend YieldN/APrice Target$25.00Consensus RatingHold Company Overview BioCardia, Inc. is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle. The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System. The Helix system is designed to facilitate precise, minimally invasive delivery of cells and biologics into viable myocardium. CardiAMP is an autologous bone marrow-derived progenitor cell therapy under investigation for its potential to improve cardiac function in patients with ischemic heart failure. Both platforms have secured investigational device exemptions from the U.S. Food and Drug Administration and are being evaluated in multi-center clinical trials. Founded in the mid-2000s and headquartered in the San Francisco Bay Area, BioCardia has assembled a leadership team with deep expertise in interventional cardiology, regenerative medicine, and medical device development. Gary S. Margulies, M.D., serves as President and Chief Executive Officer, guiding the company’s clinical programs and strategic partnerships. BioCardia collaborates with academic medical centers and clinical research organizations across the United States to advance its pipeline and ultimately bring new therapeutic options to patients suffering from heart disease.AI Generated. May Contain Errors. Read More BioCardia Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks78th Percentile Overall ScoreBCDA MarketRank™: BioCardia scored higher than 78% of companies evaluated by MarketBeat, and ranked 151st out of 866 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingBioCardia has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialBioCardia has a consensus price target of $25.00, representing about 2,375.2% upside from its current price of $1.01.Amount of Analyst CoverageBioCardia has only been the subject of 1 research reports in the past 90 days.Read more about BioCardia's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for BioCardia are expected to grow in the coming year, from ($0.71) to ($0.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioCardia is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioCardia is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioCardia has a P/B Ratio of 12.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.84% of the float of BioCardia has been sold short.Short Interest Ratio / Days to CoverBioCardia has a short interest ratio ("days to cover") of 2.68, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioCardia has recently decreased by 6.09%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioCardia does not currently pay a dividend.Dividend GrowthBioCardia does not have a long track record of dividend growth. News and Social Media3.3 / 5News Sentiment0.23 News SentimentBioCardia has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for BioCardia this week, compared to 3 articles on an average week.Search Interest7 people have searched for BCDA on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.MarketBeat Follows7 people have added BioCardia to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days. Company Ownership3.7 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $11,982.00 in company stock, which represents 0.1084% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, BioCardia insiders have bought more of their company's stock than they have sold. Specifically, they have bought $11,982.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders17.40% of the stock of BioCardia is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions20.57% of the stock of BioCardia is held by institutions.Read more about BioCardia's insider trading history. Receive BCDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioCardia and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BCDA Stock News HeadlinesBioCardia Inc (BCDA) Q1 2026 Earnings Call Highlights: Breakthroughs in Cardiac Therapy and ...May 16 at 8:31 AM | finance.yahoo.comBioCardia, Inc. (BCDA) Q1 2026 Earnings Call TranscriptMay 15 at 7:01 PM | seekingalpha.comThis stock has 30 days of quiet leftA small power equipment company with $1.5 billion in orders is flying under the radar - but not for long. When the SpaceX and xAI S-1 filing hits the SEC in June, analysts will comb through supplier disclosures and this company's name is expected to surface. Dylan Jovine has identified the ticker and laid out the full investment thesis. The stock is still quiet - but that window may be closing fast.May 16 at 1:00 AM | Behind the Markets (Ad)BioCardia Reports First Quarter 2026 Business Highlights and Financial ResultsMay 15 at 8:00 AM | globenewswire.comBioCardia, Inc. to Host Conference Call for First Quarter 2026 Financial Results on May 15May 11, 2026 | quiverquant.comQBioCardia to Host Q1 2026 Financial Results and Corporate Update Conference Call on May 15, 2026May 11, 2026 | globenewswire.comBioCardia (BCDA) Projected to Post Quarterly Earnings on WednesdayMay 11, 2026 | americanbankingnews.comBioCardia and FDA Align on Helix Transendocardial Delivery Catheter Clearance PathwaysMay 8, 2026 | markets.businessinsider.comSee More Headlines BCDA Stock Analysis - Frequently Asked Questions How have BCDA shares performed this year? BioCardia's stock was trading at $1.25 on January 1st, 2026. Since then, BCDA stock has decreased by 19.2% and is now trading at $1.01. How were BioCardia's earnings last quarter? BioCardia, Inc. (NASDAQ:BCDA) posted its quarterly earnings results on Friday, May, 15th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.17) by $0.04. Read the conference call transcript. When did BioCardia's stock split? BioCardia shares reverse split on the morning of Thursday, May 30th 2024.The 1-15 reverse split was announced on Thursday, May 30th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did BioCardia IPO? BioCardia (BCDA) raised $51 million in an initial public offering on the week of July 20th 2015. The company issued 3,900,000 shares at $12.00-$14.00 per share. Cantor Fitzgerald & Co. served as the underwriter for the IPO and Roth Capital Partners and Maxim Group were co-managers. How do I buy shares of BioCardia? Shares of BCDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BioCardia own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioCardia investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), Predictive Oncology (POAI), Abbott Laboratories (ABT), Ford Motor (F) and Wells Fargo & Company (WFC). Company Calendar Last Earnings5/15/2026Today5/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1d) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 BCDA's financial health is in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BCDA CIK925741 Webwww.biocardia.com Phone(650) 226-0120Fax310-861-5299Employees40Year Founded2002Price Target and Rating Average Price Target for BioCardia$25.00 High Price Target$25.00 Low Price Target$25.00 Potential Upside/Downside+2,375.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($1.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.23 million Net MarginsN/A Pretax MarginN/A Return on Equity-28,372.40% Return on Assets-238.22% Debt Debt-to-Equity RatioN/A Current Ratio1.12 Quick Ratio1.12 Sales & Book Value Annual Sales$60 thousand Price / Sales184.16 Cash FlowN/A Price / Cash FlowN/A Book Value$0.08 per share Price / Book12.63Miscellaneous Outstanding Shares10,940,000Free Float9,036,000Market Cap$11.05 million OptionableOptionable Beta0.56 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:BCDA) was last updated on 5/16/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | SponsoredBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...Weiss Ratings | SponsoredOil is settling in yuan now - here's what that means for goldSaudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...Golden Portfolio | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCardia, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCardia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
